Materiały źródłowe

• #1 A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value – PubMed

  https://pubmed.ncbi.nlm.nih.gov/2841422/

  A prospective study in South-East England during 15 months in 1983-1984 recruited 100 patients with acute idiopathic neuropathy. After 12 months 67% had recovered completely, 20% were still significantly disabled and 13% had died. Ten of the 13 deaths were attributable to the neuropathy. The major features in the initial assessment which were associated with persistent disability were the time taken to become bedbound, requirement for ventilation, age greater than 40 years, and small or absent compound abductor pollicis brevis muscle action potentials elicited by stimulation of the median nerve at the wrist. […] These four variables have been combined in a statistical model to predict outcome for individual patients with acute idiopathic neuropathy.

• #2 Prognosis of Diabetic Peripheral Neuropathy via Decomposed Digital Volume Pulse from the Fingertip

  https://www.mdpi.com/1099-4300/22/7/754

  Diabetic peripheral neuropathy (DPN) is a very common neurological disorder in diabetic patients. This study presents a new percussion-based index for predicting DPN by decomposing digital volume pulse (DVP) signals from the fingertip. […] After baseline measurement and blood tests, 25 diabetic patients developed DPN within the following five years. […] Multivariate analysis showed that patients who did not develop DPN in the five-year period had higher PEIDVP values than those with DPN, as determined by logistic regression model (PEIDVP: odds ratio 0.913, 95% CI 0.850 to 0.980). […] This study shows that PEIDVP can be a major protective factor in relation to the studied binary outcome (i.e., DPN or not in diabetic patients five years after baseline measurement).

• #3 Prognosis of Diabetic Peripheral Neuropathy via Decomposed Digital Volume Pulse from the Fingertip

  https://www.mdpi.com/1099-4300/22/7/754

  The investigation presented herein was conducted as follows: We hypothesized that the ensemble empirical mode decomposition (EEMD) method could be utilized for PPG-derived DVP signals to obtain two IMFs for decomposed DVP signals (IMF5 and IMF6) free of high-frequency noise. […] Our second hypothesis was that a new lower value of percussion entropy index (PEIDVP) with the adoption of decomposed DVP-derived amplitude series and PPI series could estimate the prognosis of diabetic peripheral neuropathy for diabetic patients in the five years after baseline measurement. […] This paper describes the use of decomposed DVP signals for percussion entropy analysis to assess the complexity of BRS for assessment of diabetic peripheral neuropathy prognosis. […] Diabetic patients without DPN within five years (group 2) had significantly higher PEIDVP than those who had developed DPN within five years (group 3) (0.63 ± 0.08 vs. 0.57 ± 0.08, p = 0.007, 95% CI of difference 0.016 to 0.095).

• #4 Prognosis of Diabetic Peripheral Neuropathy via Decomposed Digital Volume Pulse from the Fingertip

  https://www.mdpi.com/1099-4300/22/7/754

  Multivariate analysis showed that subjects without DPN within five years (group 2) had higher PEIDVP and PEIPPI values than those with DPN within five years (group 3) (Table 2), as determined by logistic regression model (PEIDVP: odds ratio 0.913, 95% CI 0.850 to 0.980; PEIPPI: odds ratio 0.887, 95% CI 0.791 to 0.994). […] Low PEIDVP in a diabetic patient is recognized as the primary factor in prognosis (i.e., whether the patient is going to develop DPN in the near future), and is still considered the key component in clinical practice.

• #5 Systematic review and critical appraisal of predictive models for diabetic peripheral neuropathy: Existing challenges and proposed enhancements

  https://www.wjgnet.com/1948-9358/full/v16/i4/101310.htm

  The trend of risk prediction models for diabetic peripheral neuropathy (DPN) is increasing, but few studies focus on the quality of the model and its practical application. […] The systematic review included 14 studies with a total of 26 models. The area under the receiver operating characteristic curve of the 26 models was 0.629-0.938. All studies had high risks of bias, mainly due to participants, outcomes, and analysis. […] The predictor model presented good differentiation, calibration, but there were significant methodological flaws and high risk of bias. Future studies should focus on improving the study design and study report, updating the model and verifying its adaptability and feasibility in clinical practice. […] The most common predictors included glycated hemoglobin, age, duration of diabetes, lipid abnormalities, and fasting blood glucose.

• #6 Development of risk prediction scores for diabetic peripheral neuropathy patients – Journal of Neurosciences in Rural Practice

  https://ruralneuropractice.com/development-of-risk-prediction-scores-for-diabetic-peripheral-neuropathy-patients/

  Risk prediction scores are important for early diagnosis and treatment of diseases. […] The risk prediction score developed in this study can be used by physicians to quickly assess a patients risk of DPN and select appropriate therapeutic options. Routine monitoring of modifiable risk factors can improve DPN prognosis. […] The prognosis of DPN relies on the identification of significant risk factors and early screening through comprehensive diagnosis. […] Risk prediction scores using modifiable risk predictors are crucial in identifying high-risk patients and aiding clinicians in making treatment decisions. […] Our study developed risk scores for DPN patients based on Hb%, red blood cell count, CRP, and TCSS. Regularly monitoring these risk factors improves prognosis and prevents unnecessary medication use. […] The prognosis for DPN, a disabling complication of type 2 diabetes, would be favorable if modifiable risk factors were routinely monitored. Patients who are given a risk score based on a risk prediction model for DPN can better manage their condition.

• #7 Systematic review and critical appraisal of predictive models for diabetic peripheral neuropathy: Existing challenges and proposed enhancements

  https://www.wjgnet.com/1948-9358/full/v16/i4/101310.htm

  The quality of risk prediction models is closely related to research design, modeling methods, and statistical analysis. Most included prediction models lacked rigorous research design, and the overall quality assessment of methodological aspects was suboptimal. […] Overall, the predictive models for DPN demonstrated robust performance and significant clinical relevance. Currently, there is an increasing attention in clinical practice towards constructing and utilizing these models, particularly for DPN risk prediction in diabetes patients. […] Future research should focus on exploring more controllable factors that can be improved through interventions to further enhance patient outcomes. […] Integrating DPN predictive models into clinical practice is also a challenge, requiring user-friendly tools and clear interpretive guidance for clinicians.

• #8

  https://link.springer.com/article/10.1007/s40487-021-00168-y

  The incidence of cancer and long-term survival after treatment is increasing. […] CIPN affects sensory, motor and autonomic nerves and is one of the most common adverse events caused by chemotherapeutic agents, which in severe cases leads to dose reduction or treatment cessation, with increased mortality. […] The diagnosis of CIPN relies heavily on identifying symptoms, with limited objective diagnostic approaches targeting the class of affected nerve fibres. […] Studies have consistently failed to identify at-risk cohorts, and there are no proven strategies or interventions to prevent or limit the development of CIPN. […] The increasing prevalence of CIPN demands an objective approach to identify at-risk patients in order to prevent or limit progression and effectively alleviate the symptoms associated with CIPN.

• #9

  https://link.springer.com/article/10.1007/s40487-021-00168-y

  The development of CIPN may result in prolonged infusion times, dose reduction or premature cessation of chemotherapy, which may negatively impact both treatment efficacy and patient survival. […] A meta-analysis of randomised controlled trials and cohort studies showed that around half of all patients develop CIPN during treatment. […] The prevalence of CIPN one month after finishing chemotherapy approaches 68%, and persists in approximately one third of patients beyond 6 months. […] It is therefore imperative to develop effective strategies for the early identification with prevention and more efficacious management of CIPN. […] Ultimately, there are trade-offs when treating patients with cancer, especially those with limited therapeutic options, worse prognosis or pre-existing conditions that may predispose them to chemotherapy-related complications.

• #10

  https://link.springer.com/article/10.1007/s00520-024-08484-5

  VIPN in adults presents as a sensorimotor, upper- and lower-limb neuropathy that significantly impacts disability and function. Neuropathy recovery occurs in a proportion of patients; however, VIPN symptoms may persist and continue to affect long-term quality of life. […] The natural history of development and recovery of VIPN in the adult population, however, remains ill-described. […] This study aimed to describe the natural history of VIPN in adults using a comprehensive battery of assessments including clinical grading, patient reported measures and semi-quantitative functional measures. […] At 16.315.6 months following vincristine treatment, 80.7% (n=46/57) of patients reported persistent VIPN (EORTC-QLQ-CIPN20). […] Persistent VIPN was associated with reduced spatial acuity in both the upper and lower limbs, reduced fine motor function, reduced sensory and motor nerve amplitudes and increased overall disability. […] Despite the resolution of VIPN in a proportion of patients, this analysis of chronic VIPN identified significant symptoms which lasted more than 1 year post treatment.

• #11

  https://link.springer.com/article/10.1007/s40487-021-00168-y

  The initial severity of acute OIPN also predicts progression to chronic sensory OIPN, which can be identified in 84% of patients after 25 months, with long-term impact on functionality and quality of life. […] The current hypothesis for the pathogenesis of OIPN. […] The current hypothesis for the pathogenesis of TIPN. […] The current available data on the hypothesised mechanism of VIPN is shown in Fig. 3A. […] The current hypothesis for the pathomechanism of BIPN is summarised in Fig. 3C. […] The diagnosis and assessment of CIPN lacks a reference standard, with studies utilising heterogeneous CIPN assessment tools dependent on self-reported outcome measures. […] The recent ACTTION recommendations endorse a pathomechanism-driven treatment discovery approach to CIPN. […] Detailed mechanistic research in CIPN and CIPN-related neuropathic pain is needed to address the substantial burden on the patient, families and society.

• #12 Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control | Scientific Reports

  https://www.nature.com/articles/s41598-021-81902-4

  The observed regeneration of postural control six months after completion of chemotherapy is contrasted by unchanged pathologic CIPN signs/symptoms. […] The deterioration of postural control in cancer patients during neurotoxic chemotherapy may be related to baseline sensory and motor nerve functions. […] Six months after the completion of chemotherapy, COP parameters indicate a regeneration of postural control, while CIPN signs/symptoms persist unchanged.

• #13 Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control | Scientific Reports

  https://www.nature.com/articles/s41598-021-81902-4

  Impaired postural control is often observed in response to neurotoxic chemotherapy. […] The clinical picture of CIPN comprises sensory symptoms including tingling, burning, pain, and numbness and, in more severe cases, additional motor symptoms such as muscle cramps, weakness, and wasting. […] In about 30% of patients, CIPN symptoms may persist for six months and longer after completion of neurotoxic chemotherapy. […] The pathophysiology of CIPN strongly supports a causative relationship of CIPN with impairment of postural control, but previous correlation analyses merely demonstrated low to moderate associations between various diagnostic approaches of CIPN and COP analyses. […] The regression models showed that high SNAP and low CMAP amplitudes at baseline predicted greater impairment of postural control during chemotherapy, but not during follow-up.

• #14 A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy | Scientific Reports

  https://www.nature.com/articles/s41598-020-66815-y

  Vincristine is a core chemotherapeutic drug administered to pediatric acute lymphoblastic leukemia patients. Despite its efficacy in treating leukemia, it can lead to severe peripheral neuropathy in a subgroup of the patients. Peripheral neuropathy is a debilitating and painful side-effect that can severely impact an individuals quality of life. Currently, there are no established predictors of peripheral neuropathy incidence during the early stage of chemotherapeutic treatment. […] Predicting VIPN susceptibility in patients will enable better dosage decision making tools for physicians and in turn may improve the quality of life of these patients. […] While VIPN is severe in a subpopulation of patients, another subpopulation experiences negligible neuropathy. Currently, there are neither established ways of predicting susceptibility to VIPN in patients, nor ways to treat it effectively, resulting in a suboptimal management for both the cohorts.

• #15 A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy | Scientific Reports

  https://www.nature.com/articles/s41598-020-66815-y

  The literature clearly shows that an established predictor for the early stage of the treatment is still lacking. […] In this study, we investigated the role of metabolites in predicting susceptibility of ALL pediatric patients to VIPN. […] Metabolites could not predict time point-specific TNS-PV intensity as accurately as overall susceptibility to VIPN (LN versus HN). This further strengthened our hypothesis that specific downstream metabolites can be potential biomarkers of overall neuropathy susceptibility due to treatment with vincristine. […] Our work shows that metabolomics can aid in predicting VIPN susceptibility during the early stage of treatment.

• #16 Life Expectancy with Peripheral Neuropathy | Elevation Health

  https://elevationhealthcenter.com/life-expectancy-with-peripheral-neuropathy/

  Peripheral neuropathy is a condition that affects the peripheral nerves, which are the nerves outside the brain and spinal cord. One of the most frequently asked questions by patients with peripheral neuropathy is: How long is the life expectancy with peripheral neuropathy? […] The underlying cause of the condition can significantly impact life expectancy. For example, patients with diabetes-related peripheral neuropathy may have a shorter life expectancy due to the increased risk of cardiovascular disease and other complications. […] The severity of peripheral neuropathy can also impact life expectancy. Patients with mild symptoms may have a normal life expectancy, while those with severe symptoms may have a shorter lifespan. […] Age and overall health are also important factors to consider when predicting life expectancy in people with peripheral neuropathy. Older adults may have a higher risk of developing peripheral neuropathy and may also have other health conditions that can impact life expectancy.

• #17 Life Expectancy with Peripheral Neuropathy | Elevation Health

  https://elevationhealthcenter.com/life-expectancy-with-peripheral-neuropathy/

  The treatment and management of peripheral neuropathy can also impact life expectancy. Effective management of symptoms can improve quality of life and reduce the risk of complications. […] However, studies have shown that patients with peripheral neuropathy may have a slightly lower life expectancy than the general population. […] Peripheral neuropathy itself is not usually fatal. However, it can increase the risk of complications that can impact overall health and longevity. […] Yes, the severity of peripheral neuropathy can impact life expectancy. Patients with severe symptoms may have a shorter lifespan due to the increased risk of complications and reduced ability to perform daily activities. […] Effective treatment and management of peripheral neuropathy can improve quality of life and reduce the risk of complications, which may ultimately impact life expectancy.

• #18 Life Expectancy with Peripheral Neuropathy | Elevation Health

  https://elevationhealthcenter.com/life-expectancy-with-peripheral-neuropathy/

  The factors that impact life expectancy with peripheral neuropathy are multifactorial and can include the underlying cause of the condition, the severity of symptoms, age and overall health, and the effectiveness of treatment and management strategies. […] While it is difficult to give a definitive answer to the question of how long patients with peripheral neuropathy can expect to live, it is clear that effective management of the condition can improve quality of life and potentially impact life expectancy.

• #19 Peripheral Neuropathy: What It Is, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/14737-peripheral-neuropathy

  The outlook also depends partly on your symptoms. Pain from peripheral neuropathy is usually the most disruptive symptom, but medications or other treatments may help. Autonomic symptoms are among the most serious because they involve your bodys vital functions. When those dont work correctly, it can have very severe and sometimes dangerous effects. […] Motor and sensory symptoms can also greatly disrupt your ability to work and go about your daily activities. They can cause problems sometimes severe with mobility, balance and coordination. Sensory symptoms are also disruptive, especially when they involve pain or affect your ability to control what you do with the affected body part(s). […] Lastly, treatments can make a big difference in outlook. Some treatments can greatly reduce or even stop symptoms, but this varies. Your healthcare provider is the best source of information on the outlook for your case and what you can do to help.

• #20 Peripheral Neuropathy: What It Is, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/14737-peripheral-neuropathy

  The effects of peripheral neuropathy depend on the cause, the nerves it affects, your medical history, treatments you receive and more. […] Peripheral neuropathy can be a temporary concern, or it can be permanent. How long it lasts depends on what caused it, the extent of the damage if any that it caused, the treatments and more. […] Peripheral neuropathy is most likely to be permanent with chronic conditions like type 2 diabetes, autoimmune diseases and genetic conditions. However, this can still vary, so its best to ask your healthcare provider about whats most likely in your case. […] Peripheral neuropathy is usually not dangerous, but it can have very disruptive effects on your life. These effects are usually not as severe when it only affects one nerve or a limited group of nerves. The more nerves it affects, the greater the potential impact.

Zobacz więcej